Drug Trial Radar · NCT05351346
Genotype-guided Treatment in DLBCL
Last checked: Nov 19, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,100
Planned (sponsor's estimate)
Start
Jun 1, 2022
Primary completion
Jun 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- West China Hospital; Qilu Hospital of Shandong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; The Second Hospital of Anhui Medical University; Zhongda Hospital; The First Affiliated Hospital of Soochow University; China-Japan Friendship Hospital; Tongji Hospital; Beijing Hospital; The Second Affiliated Hospital of Dalian Medical University; Zhujiang Hospital; The First Affiliated Hospital of Anhui Medical University North District; Hunan Cancer Hospital; Liaoning Cancer Hospital & Institute; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Cancer Hospital Affiliated to Xinjiang Medical University; The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Nanchang University; LanZhou University; Central South University; The Affiliated Hospital of Xuzhou Medical University; Yunnan Cancer Hospital; Henan Cancer Hospital; Fujian Medical University Union Hospital; The First Hospital of Jilin University; The First Affiliated Hospital of Anhui Medical University; Gansu Cancer Hospital; The First Affiliated Hospital of University of Science and Technology of China; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Second Affiliated Hospital of Xi'an Jiaotong University; First Affiliated Hospital Xi'an Jiaotong University; RenJi Hospital; Shandong Cancer Hospital and Institute; Affiliated Cancer Hospital of Harbin Medical University; First Affiliated Hospital of Chongqing Medical University; Fudan University; Chinese Academy of Medical Sciences; Affiliated Hospital of Nantong University; The First People's Hospital of Yunnan; Shanxi Province Cancer Hospital; Fifth Affiliated Hospital of Guangzhou Medical University; Beijing Tongren Hospital; First Affiliated Hospital of Harbin Medical University; The Third Affiliated Hospital of Wenzhou Medical University; Harbin Institute of Hematology; The First Affiliated Hospital of Guangzhou Medical University; Affiliated Hospital of Guilin Medical College; Air Force Military Medical University, China; Affiliated Zhongshan Hospital of Dalian University; Yantai Yuhuangding Hospital; The First Affiliated Hospital of Zhengzhou University; Peking University Third Hospital
- First posted
- Apr 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma
Conditions
- Diffuse Large B Cell Lymphoma
Interventions
RituximabDrug
Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
CyclophosphamideDrug
Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
DoxorubicinDrug
Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
VincristineDrug
Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
PrednisoneDrug
Prednisone PO will be administered as per the schedule specified in the respective arm.
OrelabrutinibDrug
Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
LenalidomideDrug
Lenalidomide PO will be administered as per the schedule specified in the respective arm.
DecitabineDrug
Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: Baseline up to data cut-off (up to approximately 2 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.